Teleflex (NYSE:TFX) Stock Price Expected to Rise, Mizuho Analyst Says

Teleflex (NYSE:TFX) had its target price increased by stock analysts at Mizuho from $140.00 to $145.00 in a report issued on Wednesday,Benzinga reports. The firm presently has a “neutral” rating on the medical technology company’s stock. Mizuho’s price target would suggest a potential upside of 10.05% from the stock’s previous close.

TFX has been the subject of several other research reports. Piper Sandler raised shares of Teleflex from a “neutral” rating to an “overweight” rating and lifted their price target for the stock from $140.00 to $160.00 in a report on Monday, June 8th. Weiss Ratings reissued a “sell (d)” rating on shares of Teleflex in a research report on Wednesday, June 24th. Wall Street Zen raised Teleflex from a “sell” rating to a “hold” rating in a research report on Saturday, June 27th. Raymond James Financial reiterated an “outperform” rating and set a $150.00 price target on shares of Teleflex in a research note on Friday, May 8th. Finally, Truist Financial restated a “hold” rating and issued a $143.00 price objective (up from $135.00) on shares of Teleflex in a research note on Monday, May 11th. One analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, five have issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Hold” and an average target price of $148.00.

Teleflex Stock Performance

Shares of Teleflex stock traded up $1.60 during trading hours on Wednesday, hitting $131.76. 216,447 shares of the company’s stock traded hands, compared to its average volume of 829,715. The stock has a market capitalization of $5.83 billion, a price-to-earnings ratio of -5.78, a PEG ratio of 1.01 and a beta of 0.82. Teleflex has a 12-month low of $100.18 and a 12-month high of $139.67. The company has a debt-to-equity ratio of 0.82, a current ratio of 2.55 and a quick ratio of 2.03. The company has a fifty day simple moving average of $130.21 and a 200-day simple moving average of $120.23.

Teleflex (NYSE:TFX) last posted its quarterly earnings results on Thursday, May 7th. The medical technology company reported $1.39 earnings per share for the quarter, beating the consensus estimate of $1.21 by $0.18. Teleflex had a negative net margin of 35.88% and a positive return on equity of 13.29%. The company had revenue of $548.30 million during the quarter, compared to analyst estimates of $536.91 million. During the same quarter in the prior year, the business earned $1.44 earnings per share. The firm’s revenue for the quarter was up 32.3% on a year-over-year basis. Teleflex has set its FY 2026 guidance at 6.250-6.550 EPS. Equities research analysts anticipate that Teleflex will post 6.7 EPS for the current fiscal year.

Institutional Trading of Teleflex

Institutional investors have recently added to or reduced their stakes in the stock. Assenagon Asset Management S.A. purchased a new position in Teleflex during the 2nd quarter valued at about $1,391,000. GAMMA Investing LLC boosted its position in shares of Teleflex by 60.7% in the second quarter. GAMMA Investing LLC now owns 839 shares of the medical technology company’s stock valued at $106,000 after acquiring an additional 317 shares during the period. Versant Capital Management Inc grew its stake in Teleflex by 573.4% during the second quarter. Versant Capital Management Inc now owns 431 shares of the medical technology company’s stock valued at $55,000 after acquiring an additional 367 shares in the last quarter. Glenmede Trust Co. NA lifted its stake in Teleflex by 42.1% in the 1st quarter. Glenmede Trust Co. NA now owns 6,867 shares of the medical technology company’s stock worth $821,000 after purchasing an additional 2,036 shares in the last quarter. Finally, Bank of America Corp DE lifted its stake in Teleflex by 6.4% in the 1st quarter. Bank of America Corp DE now owns 445,958 shares of the medical technology company’s stock worth $53,341,000 after purchasing an additional 27,004 shares in the last quarter. Hedge funds and other institutional investors own 95.62% of the company’s stock.

About Teleflex

Teleflex Incorporated is a diversified global provider of medical technologies, specializing in critical care and surgery. Headquartered in Wayne, Pennsylvania, the company designs, manufactures and distributes devices and solutions used by healthcare professionals in hospital, ambulatory and alternate site settings. Teleflex focuses on delivering products that support complex interventional procedures and improve patient outcomes.

The company’s offerings span several key segments, including Interventional Urology, Respiratory & Anesthesia, Surgical, Cardiac Care, Vascular and Original Equipment Manufacturer (OEM) solutions.